Tumor antigen
Showing 1 - 25 of >10,000
RT201(Tumor Antigen-specific Macrophage Tumor Vaccine)
Recruiting
- Cervical
-
Wuxi, Jiangsu, ChinaWuxi People's Hospital
Jul 3, 2023
Ependymoma Trial in Pittsburgh (biological, drug, other)
Recruiting
- Ependymoma
- HLA-A2 restricted synthetic tumor antigen
- +5 more
-
Pittsburgh, PennsylvaniaChildren's Hospital of Pittsburgh of UPMC
Oct 23, 2022
Human Leukocyte Antigen Typing and Tumor Antigen Expression
Recruiting
- Refractory Cancer
- +3 more
-
Chicago, Illinois
- +3 more
Feb 14, 2022
Esophageal Squamous Cell Carcinoma Trial in Chengdu (OCDC vaccine; NeoDC vaccine)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- OCDC vaccine; NeoDC vaccine
-
Chengdu, Sichuan, ChinaWest China Hospital
Mar 30, 2022
Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in
Not yet recruiting
- Head and Neck Cancer
- +8 more
- Tumor and HLA Profiling
- (no location specified)
Mar 31, 2023
Tumor and Peripheral Blood to Evaluate Efficacy of Cancer
Recruiting
- Lung Cancer
- Esophageal Cancer
- In vitro stimulation of Pbmc with tumor antigen nanoparticles
-
Suzhou, Jiangsu, ChinaThe first affiliated hospital of soochow university
Mar 16, 2023
Soft Tissue Sarcoma Trial in Guangzhou (TAEST16001 cells)
Active, not recruiting
- Soft Tissue Sarcoma
- TAEST16001 cells
-
Guangzhou, Guangdong, ChinaXing Zhang
Dec 13, 2022
Solid Tumor, Adult Trial in Lausanne (biological, drug, radiation)
Recruiting
- Solid Tumor, Adult
- NeoTIL
- +4 more
-
Lausanne, Vaud, Switzerlandcentre hospitalier universitaire vaudois (CHUV)
Jun 23, 2022
Glioma, Malignant Trial in Durham (Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine, Hiltonol)
Not yet recruiting
- Glioma, Malignant
- Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine
- Hiltonol
-
Durham, North CarolinaThe Preston Robert Tisch Brain Tumor Center at Duke University
Jan 19, 2023
Carcinoma, Esophagus Cancer Trial in Chengdu (Tumor antigen-sensitized DC vaccine)
Not yet recruiting
- Carcinoma
- Esophagus Cancer
- Tumor antigen-sensitized DC vaccine
-
Chengdu, Sichuan, ChinaWest China Hospital
Aug 21, 2021
Solid Tumor Trial in Washington (Tumor-associated antigen-specific T cell (TAA-T))
Recruiting
- Solid Tumor
- Tumor-associated antigen-specific T cell (TAA-T)
-
Washington, District of ColumbiaChildren's National Hospital
Oct 24, 2022
Malignancy Trial in Beijing (Al18F-PSMA-BCH PET/CT)
Recruiting
- Malignancy
- Al18F-PSMA-BCH PET/CT
-
Beijing, Chaoyang, ChinaNational Cancer Center/Cancer Hospital,Chinese Academy of Medica
Mar 7, 2023
Glioblastoma Trial in Guangzhou (Personalized cellular vaccine)
Completed
- Glioblastoma
- Personalized cellular vaccine
-
Guangzhou, Guangdong, ChinaGuangdong 999 Brain Hospital
May 23, 2022
Glioblastoma Trial in Guangzhou (Personalized cellular vaccine)
Completed
- Glioblastoma
- Personalized cellular vaccine
-
Guangzhou, Guangdong, ChinaGuangdong 999 Brain Hospital
May 23, 2022
Metastatic Oropharyngeal Carcinoma, Recurrent Oropharyngeal Carcinoma Trial in Nashville (DNA Vaccine, Human Papillomavirus
Not yet recruiting
- Metastatic Oropharyngeal Carcinoma
- Recurrent Oropharyngeal Carcinoma
- DNA Vaccine
- +6 more
-
Nashville, TennesseeVanderbilt University/Ingram Cancer Center
Mar 22, 2023
Liver Cell Carcinoma Trial in Houston (CATCH T cells, Cytoxan, Fludara)
Recruiting
- Liver Cell Carcinoma
- +7 more
- CATCH T cells
- +2 more
-
Houston, TexasHouston Methodist Hospital
Dec 19, 2022
Brain Tumor Trial in Washington (TAA-T)
Recruiting
- Brain Tumor
- TAA-T
-
Washington, District of ColumbiaBrain Tumor Institute, Children's National Medical Center
Aug 30, 2022
Multiple Myeloma Trial in Houston (TAA-specific CTLs, TAA-specific CTLs- fixed dose)
Recruiting
- Multiple Myeloma
- TAA-specific CTLs
- TAA-specific CTLs- fixed dose
-
Houston, TexasHouston Methodist Hospital
Nov 11, 2022
Carcinoma, Melanoma, Bladder Cancer Trial in Chengdu (Tumor antigen-sensitized DC vaccine and their sensitized T cells
Not yet recruiting
- Carcinoma
- +3 more
- Tumor antigen-sensitized DC vaccine and their sensitized T cells subcutaneous administration
-
Chengdu, Sichuan, ChinaWest China Hospital
Feb 10, 2022
Melanoma Trial in New York (Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs))
Completed
- Melanoma
- Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jan 12, 2023
Lung Cancer, Hepatocellular Carcinoma, Solid Tumor Trial in Guangzhou (CpG-ODN)
Recruiting
- Lung Cancer
- +2 more
- CpG-ODN
-
Guangzhou, Guangdong, ChinaThe Second Affiliated Hospital of Guangzhou Medical University
Jun 27, 2021
Posto Perative Hepatocellular Carcinoma Trial (Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab I
Not yet recruiting
- Posto Perative Hepatocellular Carcinoma
- Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab I njection
- (no location specified)
Feb 27, 2023
Solid Tumors Trial in Washington (Tumor associated antigen lymphocytes (TAA-CTL))
Active, not recruiting
- Solid Tumors
- Tumor associated antigen lymphocytes (TAA-CTL)
-
Washington, District of ColumbiaChildren's National Medical Center
Jun 1, 2022
Neuroendocrine Tumor (NET), Colorectal Cancer (CRC) Trial (CHM-2101 CAR-T cells)
Not yet recruiting
- Neuroendocrine Tumor (NET)
- Colorectal Cancer (CRC)
- CHM-2101 CAR-T cells
- (no location specified)
Sep 20, 2023
Solid Tumor Trial (HER2-E-CART cells)
Not yet recruiting
- Solid Tumor
- HER2-E-CART cells
- (no location specified)
Feb 16, 2023